Close Menu

Diagenode

Participants aim to use predictive modeling to better understand epigenetic mechanisms, while encouraging the development of new technologies and therapies.

Diagenode said the deal will bolster its suite of epigenomics services and platforms, as well as enhance its epigenetic biomarker discovery efforts.

LGC will supply DNA fragmentation instruments for clinical and agricultural biotechnology customers.

The Belgian company recently received €3.6 million to develop the signature into a clinical test within the next three years.

NEW YORK (GenomeWeb) — Becton Dickinson's BD Diagnostics division announced this week the launch of the Total Nucleic Acid suite, a kit of reagents to enable DNA- and RNA-based assay development on the automated BD Max platform.

The US Food and Drug Administration has approved BioFire Diagnostics' FilmArray Blood Culture Identification Panel. BioFire said that the 27-target panel is the most comprehensive blood culture test to be approved by the FDA.

Luminex said this week that it has received clearance from the US Food and Drug Administration for its MagPix instrument and xTAG Gastrointestinal Pathogen Panel, or GPP.

BD Diagnostics, a division of Becton Dickinson, and Belgium's Diagenode this week announced the European launch of Diagenode's influenza A and B assay for use on the BD Max molecular testing system.

NEW YORK (GenomeWeb News) – Rubicon Genomics will integrate its ThruPlex technology into Diagenode's epigenetics platforms under a partnership announced today.

Pages

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.